Tuesday - July 8, 2025
BRENTWOOD, Tenn. / Apr 22, 2025 / Business Wire / Ardent Health (NYSE: ARDT), a leading provider of healthcare in growing mid-sized urban communities across the U.S., today announced that it will issue its first quarter 2025 results after the market closes on Tuesday, May 6, 2025. A conference call will be held the following day, Wednesday, May 7, 2025, at 10:00 a.m. ET to review the Company’s financial results, discuss recent events and conduct a question-and-answer session.
A webcast of the conference call and accompanying presentation materials will be available in the Investor Relations section of Ardent’s website at ir.ardenthealth.com. To listen to a live broadcast, go to the site at least 15 minutes prior to the scheduled start time in order to register, download, and install any necessary audio software.
To participate in the live teleconference:
United States Live: | 1-888-596-4144 | |
International Live: | 1-646-968-2525 | |
Access Code: | 4437657 |
To listen to a replay of the teleconference, which will be available through May 21, 2025:
United States Replay: | 1-800-770-2030 | |
International Replay: | 1-609-800-9909 | |
Access Code: | 4437657 |
About Ardent Health
Ardent Health (NYSE: ARDT) is a leading provider of healthcare in growing mid-sized urban communities across the U.S. With a focus on people and investments in innovative services and technologies, Ardent is passionate about making healthcare better and easier to access. Through its subsidiaries, the Company delivers care through a system of 30 acute care hospitals and 280 sites of care with over 1,800 affiliated providers across six states. For more information, please visit ardenthealth.com.
Last Trade: | US$13.30 |
Daily Change: | -0.09 -0.67 |
Daily Volume: | 313,010 |
Market Cap: | US$1.900B |
May 06, 2025 March 31, 2025 February 26, 2025 |
Amneal Pharmaceuticals is a fully-integrated essential medicines company. We make healthy possible through the development, manufacturing, and distribution of generic and specialty pharmaceuticals. The Company has a diverse portfolio of over 250 products in its Generics segment and is expanding across...
CLICK TO LEARN MORECompass Therapeutics is a clinical-stage, oncology-focused biopharmaceutical company developing proprietary antibody-based therapeutics to treat multiple human diseases. The company's scientific focus is on the relationship between angiogenesis, the immune system, and tumor growth...
CLICK TO LEARN MOREEnd of content
No more pages to load